TPHA (Treponema Pallidum Hemagglutination Assay)

Overview

TPHA (Treponema Pallidum Hemagglutination Assay) is a diagnostic test used to confirm infection with Treponema pallidum, the bacterium that causes syphilis. This test works on the principle of passive hemagglutination, where erythrocytes (avian red blood cells) are coated with T. pallidum antigens. When a patient’s serum containing specific antibodies is added, binding occurs, leading to visible agglutination patterns.

The TPHA test is widely used for both qualitative and semi-quantitative detection of anti-treponemal antibodies. With a specificity of 97–99% and high sensitivity across stages of syphilis, it serves as a confirmatory tool following screening tests. Sensitivity ranges are:

1. Primary stage: 84–90%
2. Secondary stage: 100%
3. Late stage: 94–96%

Because antibody levels may remain elevated even after successful treatment, the Treponema Pallidum Hemagglutination Assay is not suitable for monitoring therapy outcomes.

Symptoms

The TPHA test is not symptom-producing itself but is used to confirm syphilis infection. The symptoms prompting its use vary depending on the stage of the disease:

1. Primary syphilis:
   1. Painless sore (chancre) at the site of infection
   2. Localized lymph node swelling
2. Secondary syphilis:
   1. Skin rashes (especially on palms and soles)
   2. Mucous membrane lesions, fever, malaise, and swollen lymph nodes
   3. Patchy hair loss
3. Late syphilis (tertiary stage):
   1. Neurological issues (neurosyphilis)
   2. Cardiovascular complications
   3. Gummatous lesions (soft tissue destruction)
4. Congenital syphilis (passed from mother to child):
   1. Stillbirth or miscarriage
   2. Severe birth defects
   3. Developmental delays

Since syphilis often shows mild or hidden symptoms, TPHA is critical for accurate confirmation.

Causes

A positive TPHA result reflects exposure to Treponema pallidum. The main causes of syphilis include:

1. Sexual Transmission:
   1. The primary mode of infection is spread through vaginal, anal, or oral sex.
2. Congenital Transmission:
   1. Infection is passed from an infected mother to the fetus during pregnancy.
3. Blood and Bodily Fluids:
   1. Rare cases through transfusions or direct exposure to infected lesions.

While TPHA confirms treponemal infection, it may also cross-react with other treponemal diseases such as yaws (T. pertenue) and pinta (T. carateum).

Risk Factors

Certain groups are at higher risk of contracting syphilis and thus may require TPHA testing:

1. Sexually Active Individuals:
   1. Especially those with multiple partners or unprotected sex.
2. Pregnant Women:
   1. Syphilis poses a high risk of congenital infection, making early screening vital.
3. HIV-Positive Individuals:
   1. Co-infection with syphilis and HIV is common due to shared transmission routes.
4. Individuals with Other STIs:
   1. Presence of another sexually transmitted infection increases susceptibility.
5. Geographic and Social Factors:
   1. People living in areas with high syphilis prevalence or lacking healthcare access.
6. Cross-Reactive Conditions:
   1. Patients with leprosy, infectious mononucleosis, or connective tissue disorders may show false-positive results.

Understanding these risk factors ensures targeted testing and timely treatment.

Prevention

Although TPHA is a diagnostic tool, preventing syphilis infection remains the key strategy:

1. Safe Sexual Practices:
   1. Consistent and correct condom use reduces transmission risk.
   2. Regular STI testing for sexually active individuals ensures early detection.
2. Prenatal Screening:
   1. All pregnant women should undergo syphilis testing, including TPHA, to prevent congenital transmission.
3. Partner Notification and Treatment:
   1. Sexual partners of infected individuals should be tested and treated promptly.
4. Education and Awareness:
   1. Public health campaigns promoting awareness of syphilis symptoms and risks.
5. Healthcare Access:
   1. Early access to healthcare and testing helps reduce undiagnosed infections.
6. Avoiding Misdiagnosis:
   1. Since TPHA cannot monitor treatment success and may cross-react, it should be combined with other confirmatory methods for accurate evaluation.